Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ESOMEPRAZOLE Cause Hyperthermia malignant? 13 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Hyperthermia malignant have been filed in association with ESOMEPRAZOLE (Esomeprazole Magnesium). This represents 0.0% of all adverse event reports for ESOMEPRAZOLE.

13
Reports of Hyperthermia malignant with ESOMEPRAZOLE
0.0%
of all ESOMEPRAZOLE reports
0
Deaths
13
Hospitalizations

How Dangerous Is Hyperthermia malignant From ESOMEPRAZOLE?

Of the 13 reports, 13 (100.0%) required hospitalization, and 12 (92.3%) were considered life-threatening.

Is Hyperthermia malignant Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ESOMEPRAZOLE. However, 13 reports have been filed with the FAERS database.

What Other Side Effects Does ESOMEPRAZOLE Cause?

Chronic kidney disease (35,281) Acute kidney injury (18,678) Renal failure (14,633) End stage renal disease (10,231) Renal injury (9,440) Gastrooesophageal reflux disease (4,746) Drug ineffective (4,420) Tubulointerstitial nephritis (4,024) Off label use (3,180) Pain (2,898)

What Other Drugs Cause Hyperthermia malignant?

SUCCINYLCHOLINE (276) SEVOFLURANE (207) PROPOFOL (205) FORANE (170) ROCURONIUM (114) FENTANYL (107) SEVOFLURANE, USP (93) ISOFLURANE (87) MIDAZOLAM (62) CISATRACURIUM (60)

Which ESOMEPRAZOLE Alternatives Have Lower Hyperthermia malignant Risk?

ESOMEPRAZOLE vs ESOMEPRAZOLE\ESOMEPRAZOLE\ESOMEPRAZOLE ESOMEPRAZOLE vs ESOMEPRAZOLE\NAPROXEN ESOMEPRAZOLE vs ESTAZOLAM ESOMEPRAZOLE vs ESTRADIOL ESOMEPRAZOLE vs ESTRADIOL CYPIONATE

Related Pages

ESOMEPRAZOLE Full Profile All Hyperthermia malignant Reports All Drugs Causing Hyperthermia malignant ESOMEPRAZOLE Demographics